Insulin Sensitivity After Breast Cancer
Recruiting · NCT05010356 · Interventional (participants receive a specific treatment) · Lead sponsor: University of Copenhagen
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Epidemiological studies have revealed that 60-80% of women with breast cancer (BC) develop metabolic disorders that are similar to those observed in conditions like type 2 diabetes. These metabolic disorders, including insulin resistance, obesity, hyperinsulinemia, and glucose intolerance, are associated with increased BC recurrence and mortality. Skeletal muscle is the major site of glucose uptake in humans. The aims of the present project are to 1) determine the involvement of insulin resistance in skeletal muscle in the metabolic disorders prevalent in BC survivors, 2) identify BC-and/or treatment-induced molecular changes in skeletal muscle from BC survivors .
Who can take part
Inclusion criteria
- Premenopausal women operated for breast cancer and after completing adjuvant chemotherapy and no earlier than 3 weeks after its termination
- BMI: 25-30
- Healthy controls will be included matched by gender, weight, age, and level of physical activity to the patient group included as subjects
Exclusion criteria
- Known postmenopause occurred at the time of diagnosis of breast cancer
- Alcohol intake of\> 7 items / week
- Smoker
- Already known Type 2 diabetes mellitus or metabolic syndrome and medical treatment thereof.
- Cardiovascular disease and its medical treatment
- Impaired mobility
Where it is running
1 location listed.
- University of Copenhagen - Copenhagen, DK, Denmark